212 related articles for article (PubMed ID: 11994126)
21. Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.
Lee DH; Rötger C; Appeldoorn CC; Reijerkerk A; Gladdines W; Gaillard PJ; Linker RA
J Neuroimmunol; 2014 Sep; 274(1-2):96-101. PubMed ID: 25037177
[TBL] [Abstract][Full Text] [Related]
22. [Influence of particle size and MePEG molecular weight on in vitro macrophage uptake and in vivo long circulating of stealth nanoparticles in rats].
Fang C; Shi B; Hong MH; Pei YY; Chen HZ
Yao Xue Xue Bao; 2006 Apr; 41(4):305-12. PubMed ID: 16856473
[TBL] [Abstract][Full Text] [Related]
23. Chapter 3 - Colloidal systems for CNS drug delivery.
Costantino L; Tosi G; Ruozi B; Bondioli L; Vandelli MA; Forni F
Prog Brain Res; 2009; 180():35-69. PubMed ID: 20302828
[TBL] [Abstract][Full Text] [Related]
24. Peptide-functionalized polymeric nanoparticles for active targeting of damaged tissue in animals with experimental autoimmune encephalomyelitis.
Führmann T; Ghosh M; Otero A; Goss B; Dargaville TR; Pearse DD; Dalton PD
Neurosci Lett; 2015 Aug; 602():126-32. PubMed ID: 26141613
[TBL] [Abstract][Full Text] [Related]
25. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis.
Kizelsztein P; Ovadia H; Garbuzenko O; Sigal A; Barenholz Y
J Neuroimmunol; 2009 Aug; 213(1-2):20-5. PubMed ID: 19564052
[TBL] [Abstract][Full Text] [Related]
26. Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE.
Knobler RL; Marini JC; Goldowitz D; Lublin FD
J Neuropathol Exp Neurol; 1992 Jan; 51(1):36-9. PubMed ID: 1371310
[TBL] [Abstract][Full Text] [Related]
27. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
28. Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate receptor antagonist memantine.
Paul C; Bolton C
J Pharmacol Exp Ther; 2002 Jul; 302(1):50-7. PubMed ID: 12065699
[TBL] [Abstract][Full Text] [Related]
29. Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis.
Cavaletti G; Cassetti A; Canta A; Galbiati S; Gilardini A; Oggioni N; Rodriguez-Menendez V; Fasano A; Liuzzi GM; Fattler U; Ries S; Nieland J; Riccio P; Haas H
Mol Pharm; 2009; 6(5):1363-70. PubMed ID: 19281192
[TBL] [Abstract][Full Text] [Related]
30. Blood-brain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat.
Juhler M; Barry DI; Offner H; Konat G; Klinken L; Paulson OB
Brain Res; 1984 Jun; 302(2):347-55. PubMed ID: 6610460
[TBL] [Abstract][Full Text] [Related]
31. N-Methyl-D-aspartate (NMDA) receptor involvement in central nervous system prostaglandin production during the relapse phase of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE).
Bolton C; Wood EG; Ayoub SS
Fundam Clin Pharmacol; 2013 Oct; 27(5):535-43. PubMed ID: 22742874
[TBL] [Abstract][Full Text] [Related]
32. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: influence of PEG coating on the particle size, drug release rate and phagocytic uptake.
Fontana G; Licciardi M; Mansueto S; Schillaci D; Giammona G
Biomaterials; 2001 Nov; 22(21):2857-65. PubMed ID: 11561891
[TBL] [Abstract][Full Text] [Related]
33. Nanotechnological advances for the delivery of CNS therapeutics.
Wong HL; Wu XY; Bendayan R
Adv Drug Deliv Rev; 2012 May; 64(7):686-700. PubMed ID: 22100125
[TBL] [Abstract][Full Text] [Related]
34. Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs.
Saganuwan SA
Cent Nerv Syst Agents Med Chem; 2018 Jan; 18(1):32-38. PubMed ID: 28828968
[TBL] [Abstract][Full Text] [Related]
35. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity.
Schreibelt G; Musters RJ; Reijerkerk A; de Groot LR; van der Pol SM; Hendrikx EM; Döpp ED; Dijkstra CD; Drukarch B; de Vries HE
J Immunol; 2006 Aug; 177(4):2630-7. PubMed ID: 16888025
[TBL] [Abstract][Full Text] [Related]
36. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis.
Schmidt J; Metselaar JM; Wauben MH; Toyka KV; Storm G; Gold R
Brain; 2003 Aug; 126(Pt 8):1895-904. PubMed ID: 12805101
[TBL] [Abstract][Full Text] [Related]
37. Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.
Meng J; Agrahari V; Youm I
J Neuroimmune Pharmacol; 2017 Mar; 12(1):84-98. PubMed ID: 27449494
[TBL] [Abstract][Full Text] [Related]
38. Polymeric nanoparticles for drug delivery to the central nervous system.
Patel T; Zhou J; Piepmeier JM; Saltzman WM
Adv Drug Deliv Rev; 2012 May; 64(7):701-5. PubMed ID: 22210134
[TBL] [Abstract][Full Text] [Related]
39. Relation between the increase in the diffusional permeability of the blood-central nervous system barrier and other changes during the development of experimental allergic encephalomyelitis in the Lewis rat.
Daniel PM; Lam DK; Pratt OE
J Neurol Sci; 1983; 60(3):367-76. PubMed ID: 6415240
[TBL] [Abstract][Full Text] [Related]
40. Involvement of Claudin-11 in Disruption of Blood-Brain, -Spinal Cord, and -Arachnoid Barriers in Multiple Sclerosis.
Uchida Y; Sumiya T; Tachikawa M; Yamakawa T; Murata S; Yagi Y; Sato K; Stephan A; Ito K; Ohtsuki S; Couraud PO; Suzuki T; Terasaki T
Mol Neurobiol; 2019 Mar; 56(3):2039-2056. PubMed ID: 29984400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
